

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): June 15, 2022

MONTE ROSA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware <small>(State or other jurisdiction of incorporation)</small>	001-40522 <small>(Commission File Number)</small>	84-3766197 <small>(I.R.S. Employer Identification No.)</small>
645 Summer Street, Suite 102 Boston, MA 02210 <small>(Address of principal executive offices, including zip code)</small>		
(617) 949-2643 <small>(Registrant's telephone number, including area code)</small>		
Not Applicable <small>(Former Name or Former Address, if Changed Since Last Report)</small>		

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value per share	GLUE	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07 Submission of Matters to Vote of Security Holders

Monte Rosa Therapeutics, Inc (the "Company") held its Annual Meeting of Stockholders on June 15, 2022 (the "Annual Meeting") in a virtual-only format via live webcast. At the Annual Meeting, the Company's stockholders of record as of April 20, 2022 (the "Record Date") considered and voted on the two proposals set forth below, each of which is described in greater detail in the Company's Proxy Statement, filed with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended on April 27, 2022. As of the Record Date, the number of shares of the Company's common stock, \$0.0001 par value per share ("Common Stock"), outstanding and entitled to vote at the Annual Meeting was 46,656,249. The number of shares of Common Stock present or represented by valid proxy at the Annual Meeting was 43,785,969, thus establishing a quorum for the Annual Meeting. Shares present virtually during the Annual Meeting were considered shares of Common Stock represented in person at the Annual Meeting. Each share of Common Stock was entitled to one vote with respect to matters submitted to the Company's stockholders at the Annual Meeting. The final voting results are set forth below.

The following is a summary of the matters voted on at the Annual Meeting.

Proposal 1 - Election of Class I Director Nominees

The stockholders of the Company elected Christine Siu, M.B.A. and Kimberly L. Blackwell, M.D. as Class I directors of the Company, each for a three-year term ending at the annual meeting of stockholders to be held in 2025 and until their successor have been duly elected and qualified or until their earlier resignation or removal. The results of the stockholders' vote with respect to the election of the Class I directors were as follows:

	Votes For	Votes Withheld	Broker Non-Votes
Christine Siu, M.B.A.	40,031,134	1,535,338	2,219,497
Kimberly L. Blackwell, M.D.	34,701,825	6,853,459	2,230,685

Proposal 2 - Ratification of Appointment of the Company's Independent Registered Public Accounting Firm

The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022. The results of the stockholders' vote with respect to such ratification were as follows:

Votes For	Votes Against	Abstain
43,776,605	1,664	7,700

No other matters were submitted to or voted on by the Company's stockholders at the Annual Meeting.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Monte Rosa Therapeutics, Inc.

Date: June 15, 2022

By: /s/ Markus Warmuth

Markus Warmuth

President and Chief Executive Officer
